

## **Data Sheet**


Product Name: Basimglurant
Cat. No.: CS-3388
CAS No.: 802906-73-6
Molecular Formula: C18H13CIFN3

Molecular Weight: 325.77
Target: mGluR

Pathway: GPCR/G Protein; Neuronal Signaling

Solubility: DMSO :  $\geq$  33.33 mg/mL (102.31 mM); H2O : < 0.1 mg/mL

(insoluble)



## **BIOLOGICAL ACTIVITY:**

Basimglurant (RG7090) is a potent, selective and orally available **mGlu5** negative allosteric modulator with a  $K_d$  of 1.1 nM. IC50 & Target: Kd: 1.1 nM (mGlu5)<sup>[1]</sup> **In Vitro**: [³H]-basimglurant saturation analysis on recombinant human mGlu5 reveals monophasic saturation isotherms with  $K_d$  of 1.1 nM. In competition binding experiments on human recombinant mGlu5, Basimglurant (RG7090) fully displaces [³H]-MPEP with a  $K_i$  of 35.6 nM and [³H]-ABP688 with a  $K_i$  of 1.4 nM. In HEK293 cells stably expressing human mGlu5, Basimglurant (RG7090) inhibits quisqualate induced  $Ca^{2+}$  mobilization with an  $IC_{50}$  of 7.0 nM and [³H]-inositolphosphate accumulation with an  $IC_{50}$  of 5.9 nM. Basimglurant (RG7090) shows similar potencies in radioligand binding and functional assay on human and rodent mGlu5 receptor orthologues<sup>[1]</sup>. **In Vivo**: Basimglurant (RG7090) is a potent, selective, and safe mGlu5 inhibitor with good oral bioavailability and long half-life supportive of once-daily administration, good brain penetration, and high in vivo potency. It has antidepressant properties which are corroborated by its functional magnetic imaging (fMRI) profile, as well as anxiolytic-like and antinociceptive features<sup>[1]</sup>. It is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. In the Vogel conflict drinking test, Basimglurant dose dependently increases the drinking time. The total plasma exposure of efficacious doses of Basimglurant (RG7090) ranges from 5 ng/mL (0.03 mg/kg) to 37 ng/mL (0.3 mg/kg)<sup>[2]</sup>.

## PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: <sup>[1]</sup>Rats: For intravenous PK, Basimglurant (RG7090) is formulated in N-methyl-pyrollidone (NMP)/saline (30%/70%) as vehicle and administered at a volume of 2 mL/kg. For oral gavage (p.o.) the compound is administered as suspension using gelatine/saline (7.5%/0.62% in water) at an administration volume of 4 mL/kg<sup>[1]</sup>.


Monkey: For intravenous PK, Basimglurant (RG7090) is formulated in cyclodextrin solution as vehicle and administered at a volume of 2 mL/kg. For oral gavage (p.o.), the compound is administered in capsule (2 mg in size-2 capsules, i.e. ~0.3 mg/kg) to fasted or fed monkeys in a cross-over design<sup>[1]</sup>.

## References:

[1]. Lindemann L, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther. 2015 Apr;353(1):213-33.

[2]. Jaeschke G, et al. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Page 1 of 2 www.ChemScene.com



**CAIndexNames**:

Page 2 of 2 www.ChemScene.com